Find in Library

The ideal or most appropriate insulin therapy system is one that achieves or comes close to maintaining blood glucose within normal physiological ranges. Reaching this goal is the current challenge in Biotechnology applied to Diabetes. The developments of rapid analog insulins, continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusers (CSII) were and are simultaneously and progressively providing the necessary tools to approach the long-awaited goal. However, the paradigm to make this possible arose from the automated insulin delivery (AID) or artificial páncreas (AP) systems, in which engineering added to advances in CSII and CGM, a third component called "control algorithm" who regulates the administration of insulin by the infuser according to the value of interstitial glucose transmitted by the CGM.